TITLE:
A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.

CONDITION:
HIV Infections

INTERVENTION:
Adefovir

SUMMARY:

      To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of PMEA ( adefovir )
      when administered daily by intravenous (IV) and/or subcutaneous (SC) injection in patients
      with advanced HIV disease.
    

DETAILED DESCRIPTION:

      Patients receive a single IV or SC dose of PMEA daily for 4 weeks. A maximum tolerated dose
      will be defined for these regimens.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 60 Years
Criteria:

        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Other antiretroviral therapy IF on a stable dose for at least 4 weeks prior to study
             entry.

          -  Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole
             (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole IF on a stable
             prophylactic regimen for at least 4 weeks prior to study entry.

        Patients must have:

          -  HIV seropositivity.

          -  Elevated p24 antigen (> 40 pg/ml).

          -  Mean CD4 count <= 100 cells/mm3.

          -  Life expectancy of at least 3 months.

        Prior Medication:

        Allowed:

          -  Other prior antiretroviral therapy.

          -  Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole
             (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Inadequate venous access.

          -  Active serious infection (other than HIV infection) requiring parenteral antibiotic
             therapy.

          -  Clinically significant cardiac disease, including symptoms of ischemia, congestive
             heart failure, or arrhythmia.

          -  Psychiatric disturbance or illness that may affect compliance.

          -  Malignancy other than Kaposi's sarcoma.

        Concurrent Medication:

        Excluded:

          -  Investigational agents other than stavudine (d4T).

          -  Interferon-alpha.

          -  Ganciclovir.

          -  Foscarnet.

          -  Diuretics.

          -  Amphotericin B.

          -  Aminoglycoside antibiotics.

          -  Other nephrotoxic agents.

          -  Acyclovir at doses >= 2 g/day.

        Prior Medication:

        Excluded within 2 weeks prior to study entry:

          -  Investigational agents other than stavudine (d4T).

          -  Interferon-alpha.

          -  Ganciclovir.

          -  Foscarnet.

          -  Diuretics.

          -  Amphotericin B.

          -  Aminoglycoside antibiotics.

          -  Other nephrotoxic agents.

        Excluded within 4 weeks prior to study entry:

          -  Systemic therapy for Kaposi's sarcoma. Substance abuse.
      
